目的 探讨芪药消渴胶囊联合恩格列净片治疗2型糖尿病的临床疗效。方法 将2024年5月—2025年5月永州市第一人民医院就诊的102例2型糖尿病患者作为研究对象，所有患者以随机数字表法分为对照组和治疗组，每组各51例。对照组口服恩格列净片，1片/次，1次/d。治疗组患者在对照组基础上口服芪药消渴胶囊，6粒/次，3次/d。两组患者持续治疗12周。比较两组患者的临床疗效、生活质量、血管内皮功能、血清指标。结果 治疗后，对照组的总有效率为84.31%，明显低于治疗组的总有效率96.08%，两组组间比较差异显著（P＜0.05）。两组治疗后的糖尿病特异性生命质量量表（A-DQQL）评分明显降低，血管内皮依赖性舒张功能（FMD）显著升高（P＜0.05），且治疗组治疗后A-DQQL评分低于对照组，FMD高于对照组（P＜0.05）。两组治疗后的空腹血糖（FBG）、空腹胰岛素（FINS）、糖化血红蛋白（HbA1c）明显降低，空腹C肽（FCP）明显升高（P＜0.05）；治疗组治疗后的FBG、FINS、HbA1c明显低于对照组，FCP明显高于对照组（P＜0.05）。两组治疗后的糖基化终产物（AGE）、丙二醛（MDA）明显降低，谷胱甘肽（GSH）明显升高（P＜0.05）；治疗组治疗后的AGE、MDA低于对照组，GSH高于对照组（P＜0.05）。结论 芪药消渴胶囊联合恩格列净片可提高2型糖尿病的临床疗效，提高生活质量，改善血管内皮功能，改善血糖，减轻氧化应激反应。

Objective To investigate the clinical efficacy of Qiyao Xiaoke Capsules combined with Empagliflozin Tablets in treatment of type 2 diabetes mellitus. Methods The study included 102 patients with type 2 diabetes who were treated in Yongzhou First People’s Hospital from May 2024 to May 2025. All patients were divided into control group and treatment group according to the random number table method, with 51 cases in each group. The control group was po administered with Empagliflozin Tablets, 1 tablets/time, once daily. The treatment group received Qiyao Xiaoke Capsules orally on the base of the control group, 6 capsules/time, three times daily. Two groups were treated for 12 weeks. Clinical efficacy, quality of life, vascular endothelial function, and serum indicators were compared between two groups. Results After treatment, the total effective rate of the control group was 84.31%, significantly lower than the total effective rate of 96.08% in the treatment group, and the difference between the groups was significant (P < 0.05). After treatment, the ‌adjusted diabetes quality of life scale (A-DQQL) score in two groups was significantly reduced, but the vascular endothelium dependent diastolic function (FMD) was significantly increased (P < 0.05). The A-DQOL score in the treatment group was lower than that in the control group, but the FMD was higher than that in the control group (P < 0.05). After treatment, fasting blood glucose (FBG), fasting insulin (FINS), and glycated hemoglobin (HbA1c) were significantly reduced in two groups, while fasting C-peptide (FCP) was significantly increased (P < 0.05). The FBG, FINS, and HbA1c levels in the treatment group were significantly lower than those in the control group, while the FCP level was significantly higher than that in the control group (P < 0.05). After treatment, the glycation end products (AGE) and malondialdehyde (MDA) in two groups were significantly reduced, while glutathione (GSH) was significantly increased (P < 0.05). The AGE and MDA levels in the treatment group were lower than those in the control group, while GSH levels were higher than those in the control group (P < 0.05). Conclusion Qiyao Xiaoke Capsules combined with Empagliflozin Tablets can improve the clinical efficacy of type 2 diabetes, improve the quality of life, improve vascular endothelial function, improve blood sugar, and reduce oxidative stress.

R977

湖南省自然科学基金项目（2024JJ7583）